Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar-Apr;31(2):190-193.
doi: 10.4103/ijn.IJN_388_19. Epub 2021 Mar 27.

Rosuvastatin-Induced Rhabdomyolysis: A Case Report

Ravindra Nikalji  1 , Suvadeep Sen  2
Affiliations
Case Reports

Rosuvastatin-Induced Rhabdomyolysis: A Case Report

Ravindra Nikalji et al. Indian J Nephrol. 2021 Mar-Apr.

Abstract

Rosuvastatin is a recently approved statin and used widely across the globe for primary and secondary prevention of atherosclerotic cardiovascular heart disease. It has the highest lipid-lowering property among all statins and relatively well tolerated. Rhabdomyolysis is a rare but potentially serious adverse effect. The present report highlights the case of a patient admitted with proximal myopathy with severe rhabdomyolysis and acute kidney injury associated with life-threatening hyperkalemia. The symptoms appeared within 1 month of starting rosuvastatin. He required temporary dialysis to overcome the crisis. His myopathy and kidney injury were completely reversible after a few months of stopping the drug. In this report, we have also discussed the various risk factors for developing myopathy with statins and the importance of strict pharmacovigilance, and a greater caution among physicians while using this drug.

Keywords: Acute kidney injury; rhabdomyolysis; rosuvastatin.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Cholesterol Treatment Trialists (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. - PMC - PubMed
    1. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395–410. - PubMed
    1. Jacobson TA. Overcoming 'ageism' bias in the treatment of hypercholesterolaemia: A review of safety issues with statins in the elderly. Drug Saf. 2006;29:421–48. - PubMed
    1. Davidson MH. Rosuvastatin in elderly patients. Drugs Aging. 2007;24:933–44. - PubMed
    1. Vrkić Kirhmajer M, Macolić Šarinić V, Šimičević L, Ladić I, Putarek K, Banfić L, et al. Rosuvastatin-induced rhabdomyolysis-possible role of ticagrelor and patients' pharmacogenetic profile. Basic Clin Pharmacol Toxicol. 2018;123:509–18. - PubMed

Publication types